Histiocytic neoplasms, version 2.2021

Ronald S. Go, Eric Jacobsen, Robert Baiocchi, Ilia Buhtoiarov, Erin B. Butler, Patrick K. Campbell, Don W. Coulter, Eli Diamond, Aron Flagg, Aaron M. Goodman, Gaurav Goyal, Dita Gratzinger, Paul C. Hendrie, Meghan Higman, Michael D. Hogarty, Filip Janku, Reem Karmali, David Morgan, Anne C. Raldow, Alexandra StefanovicSrinivas K. Tantravahi, Kelly Walkovich, Ling Zhang, Mary Anne Bergman, Susan D. Darlow

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Histiocytic neoplasms are rare hematologic disorders accounting for less than 1% of cancers of the soft tissue and lymph nodes. Clinical presentation and prognosis of these disorders can be highly variable, leading to challenges for diagnosis and optimal management of these patients. Treatment often consists of systemic therapy, and recent studies support use of targeted therapies for patients with these disorders. Observation (“watch and wait”) may be sufficient for select patients with mild disease. These NCCN Guidelines for Histiocytic Neoplasms include recommendations for diagnosis and treatment of adults with the most common histiocytic disorders: Langerhans cell histiocytosis, Erdheim-Chester disease, and Rosai-Dorfman disease.

Original languageEnglish (US)
Pages (from-to)1277-1303
Number of pages27
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume19
Issue number11
DOIs
StatePublished - Nov 2021

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Histiocytic neoplasms, version 2.2021'. Together they form a unique fingerprint.

Cite this